Results 181 to 190 of about 42,628 (216)
Some of the next articles are maybe not open access.
Cholinesterase inhibitors and memory
Chemico-Biological Interactions, 2010A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the therapeutic effect is usually short-lasting. In experimental animals, ChEIs exert three main actions: inhibit cholinesterase (ChE), increase extracellular levels of brain ...
PEPEU, GIANCARLO +1 more
openaire +3 more sources
Clinical Pharmacokinetics of Cholinesterase Inhibitors
Clinical Pharmacokinetics, 1986This review deals mainly with the pharmacokinetics of the reversible quaternary cholinesterase inhibitors neostigmine, pyridostigmine and edrophonium, which are mainly used to antagonise non-depolarising neuromuscular blockade in general anaesthesia and in the symptomatic treatment of myasthenia gravis.
S M, Aquilonius, P, Hartvig
openaire +2 more sources
Drug Interactions with Cholinesterase Inhibitors
Drugs & Aging, 2003Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimer's disease. This population often has numerous comorbidities and receives treatment with multiple medications. The astute clinician should remain mindful of possible drug interactions, both pharmacokinetic and pharmacodynamic, that may occur with concomitant ...
Jennifer L, Defilippi, M Lynn, Crismon
openaire +2 more sources
Cholinesterase Inhibitors Stabilize Alzheimer's Disease
Annals of the New York Academy of Sciences, 2000Abstract: During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted into three drugs being registered for the first time in the USA and Europe for this specific indication. All three are cholinesterase inhibitors (ChEI).
openaire +3 more sources
Pharmacokinetic studies of cholinesterase inhibitors
Acta Neurologica Scandinavica, 2009The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this class, physostigmine has an elimination half-life of 20-30 min.
M, Johansson, A, Nordberg
openaire +2 more sources
Ten years of cholinesterase inhibitors
International Journal of Geriatric Psychiatry, 2009AbstractIn this editorial we have summarised ten years of evidence relating to the use of cholinesterase inhibitors in Alzheimer's and other dementias. We have presented this evidence in the context of the evolution of public and professional awareness of dementia and its management and prescribing patterns over this time frame. We also briefly outline
Joanne, Rodda, Zuzana, Walker
openaire +2 more sources
Cholinesterase inhibitors: beyond Alzheimer’s disease
Expert Review of Neurotherapeutics, 2010Cholinesterase inhibitors (ChEIs) are widely licensed for the symptomatic treatment of Alzheimer’s disease, but their use has also been examined in a wide variety of neurological disorders besides Alzheimer’s disease, and this article reviews these uses.
openaire +2 more sources
Cholinesterases and Cholinesterase Inhibitors
Current Enzyme Inhibition, 2008Sarka Stepankova, Karel Komers
openaire +1 more source
Cholinesterase inhibitors for Alzheimer's disease
Cochrane Database of Systematic Reviews, 2006Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all ...
openaire +2 more sources